Liphorus Pharmaceuticals
Montréal, Quebec, Canada
About Liphorus Pharmaceuticals
Liphorus Pharmaceuticals develops small compounds that target PCSK9 to treat hypercholesterolemia. Along with this initial round of funding, the company has a research agreement with the IRCM that will enable it to create and validate compounds that target PCSK9.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2014)
- Website: liphorus.com
- Phone: [email protected]
Industries & Categories
Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/liphorus-pharmaceuticals-2470373 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.